



LabCorp Service **Announcement**

LabCorp Launches Interleukin 28B Polymorphism (*IL28B*) Genotype Test to Support Individualized Treatment Decisions for Patients with Hepatitis C Viral Infection.

As a specialty provider of HCV testing services, LabCorp is committed to being at the forefront of new tests and technologies to support HCV-treating physicians and their patients. **Beginning July 12, 2010**, LabCorp will be one of the first clinical reference laboratory to offer the *IL28B* polymorphism (rs12979860) genotype test.

A recent genome-wide association study (GWAS) identified *IL28B* genetic polymorphism as a strong predictor of response to pegIFN plus ribavirin therapy in HCV genotype 1-infected individuals.¹ Combination pegIFN and ribavirin therapy in HCV genotype 1-infected patients was 2- to 3-fold more likely to be successful if patients were carriers of the CC (rs12979860) genotype as compared with either the CT or TT genotypes.^{1,2} Similar associations were observed across various racial groups including European Americans, African Americans, and Hispanics.¹ *IL28B* genotype was the strongest pretreatment predictor of sustained viral response, showing a higher odds ratio (OR= 5.2) than any of the other independently associated predictors of treatment response such as baseline viral RNA level, fibrosis stage, ethnicity, or fasting glucose levels.²

Assay features for the *IL28B* polymorphism genotype include:

- Simple to interpret results of CC, CT, or TT genotype
- Performed on buccal swab or whole blood in EDTA collection tube
- 5- to 7-day result turnaround time
- Use of existing CPT billing codes

.....

For additional information, please contact your LabCorp account representative or call 800-345-4363.

Test Name	<i>IL28B</i> Polymorphism Genotype by RT-PCR
Test Number	480630
CPT Codes	83891, 83898, 83896 x 2, 83912

References

1. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature*. 2009;461:399-401.
2. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology*. 2010;139:120-129.

